Summary of the interim report

The "Company" or "Xintela" refers to Xintela AB (publ), corporate registration number 556780-3480.

Third quarter July 1 - September 30, 2021
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 10,910 (loss: 8,315).
Loss per share* was SEK 0.13 (loss: 0.14).
At September 30, 2021, the equity/assets ratio** was 77 % (47).

The period January 1 - September 30, 2021
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 31,752 (loss: 24,922).
Loss per share* was SEK 0.36 (loss: 0.43).

* Earnings/loss per share: Profit/loss for the period divided by 89,134,021 shares, which was the number of registered shares at September 30, 2021. In the year-earlier period, the Company had 57,542,856 registered shares.
** Equity/assets ratio: Equity divided by total capital.
Amounts in parentheses: Comparative period of the preceding year.

Significant events in the third quarter of 2021
· Xintela incorporates subsidiary in Australia. (July 1, 2021)
· The Extraordinary General Meeting of Xintela AB approves the Board's proposal for a new issue of shares. (July 5, 2021)
· Xintela signs with Australian CRO for clinical study. (July 16, 2021)
· Xintela to expand clinical development of stem cell product XSTEM. (September 30, 2021)

Significant events after the end of the period
· Targinta selects lead drug candidate for triple-negative breast cancer. (October 15, 2021)
· Xintela taking EQSTEM, a stem cell product for horses, towards the market. (October 27, 2021)
· New board of directors appointed in Targinta AB. (October 29, 2021)
· Update on status and strategi for Xintela and Targinta. (November 4, 2021)
· Xintela receives a loan of SEK 9 million. (November 18, 2021)

The complete report is attached as pdf and is available on the company's website https://www.xintela.se/en/investors#reports.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on November 19, 2021.

About Xintela
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is now entering a clinical development phase for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

The following documents can be retrieved from beQuoted
Xintela 2021 Q3 EN FINAL.pdf